AI-Derived Sarcopenia Metrics Predict Survival Benefit from Anti-EGFR Therapy in RAS Wild-Type Metastatic Colorectal Cancer
A deep learning analysis of the PanaMa trial reveals that the benefit of adding panitumumab to maintenance therapy for RAS wild-type mCRC is significantly higher in patients with a high muscle-bone ratio, suggesting a new AI-driven approach to personalized oncology.